Episode

Strategies and Advances in AML

Podcast: Treating Blood Cancers
Published: Jun 12, 2025
Duration seconds: 2282
Processing state: not_requested
Canonical source: https://treatingbloodcancers.org/e104/?utm_source=rss&utm_medium=rss&utm_campaign=e104
Audio: https://media.blubrry.com/treating_blood_cancers/content.blubrry.com/treating_blood_cancers/TBC_E104-Dr_Borate-AML_mixdown_Production.mp3
JSON: /v1/public/podcasts/treating-blood-cancers-14318/episodes/strategies-and-advances-in-aml
Markdown: /podcast/treating-blood-cancers-14318/strategies-and-advances-in-aml.md

Actions

POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/strategies-and-advances-in-aml/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/treating-blood-cancers-14318/strategies-and-advances-in-aml.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Uma Borate, MBBS, MS, The Ohio State University, Columbus, OH Recorded on May 27, 2025 Uma Borate, MBBS, MS Associate Professor, Division of Hematology Acute Leukemia Clinical Research Disease Group Leader The Ohio State University Columbus, OH What’s changing in acute myeloid leukemia (AML)? Join Dr. Uma Borate from The Ohio State University in Columbus, Ohio, as she dives into emerging breakthroughs in AML biology, including molecular drivers, menin inhibitors, and the challenges of developing bispecifics and CAR T-cell therapies. She also shares updates from the LLS Beat AML ® Master Clinical Trial and ongoing clinical trials, and reflects on the evolving treatment landscape across age groups. Don’t miss this dynamic conversation packed with expertise and hope for the future of AML!